Table 1.
Sites of First Disease Failure According to Random Treatment Assignment and Accounting for Selective Crossover
| Disease Failure* | Treatment |
|||||
|---|---|---|---|---|---|---|
| Letrozole (n = 2,463) |
Tamoxifen (n = 2,459) |
Total (N = 4,922) |
||||
| No. | % | No. | % | No. | % | |
| Overall | 509 | 20.7 | 544 | 22.1 | 1,053 | 21.4 |
| Local | 30 | 1.2 | 44 | 1.8 | 74 | 1.5 |
| Contralateral breast | 30 | 1.2 | 34 | 1.4 | 64 | 1.3 |
| Regional | 19 | 0.8 | 16 | 0.7 | 35 | 0.7 |
| Distant | 239 | 9.7 | 254 | 10.3 | 493 | 10.0 |
| Soft tissue | 15 | 0.6 | 21 | 0.9 | 36 | 0.7 |
| Bone | 109 | 4.4 | 111 | 4.5 | 220 | 4.5 |
| Viscera | 115 | 4.7 | 122 | 5.0 | 237 | 4.8 |
| Second (nonbreast) malignancy | 101 | 4.1 | 106 | 4.3 | 207 | 4.2 |
| Head and neck | 3 | — | 3 | — | 6 | — |
| Thyroid | 4 | — | 5 | — | 9 | — |
| Lung | 8 | — | 11 | — | 19 | — |
| Lung carcinoid | 1 | — | — | — | 1 | — |
| Esophageal | 3 | — | — | — | 3 | — |
| Gastric | 6 | — | 4 | — | 10 | — |
| Pancreatic | 3 | — | 4 | — | 7 | — |
| Pancreatic and renal | 1 | — | — | — | 1 | — |
| Hepatic/Biliary | 1 | — | 3 | — | 4 | — |
| Colorectal | 20 | — | 23 | — | 53 | — |
| Gastrointestinal NOS | — | — | 1 | — | 1 | — |
| Renal | 3 | — | 9 | — | 12 | — |
| Urothelial | 2 | — | 2 | — | 4 | — |
| Ovarian | 7 | — | 7 | — | 14 | — |
| Endometrial | 6 | — | 19 | — | 25 | — |
| Mixed Muellerian tumor | — | — | 2 | — | 2 | — |
| Uterine sarcoma | — | — | 2 | — | 2 | — |
| Cervical | 4 | — | 1 | — | 5 | — |
| Vaginal/vulvar | 4 | — | — | — | 4 | — |
| CNS glioblastoma | 1 | — | 1 | — | 2 | — |
| Melanoma | 11 | — | 2 | — | 13 | — |
| Melanoma and lung | 1 | — | — | — | 1 | — |
| Leukemia | 4 | — | 4 | — | 8 | — |
| Lymphoma NHL | 4 | — | 3 | — | 7 | — |
| Multiple myeloma | 3 | — | — | — | 3 | — |
| Unknown† | 1 | — | — | — | 1 | — |
| Death without prior cancer event | 87 | 3.5 | 86 | 3.5 | 173 | 3.5 |
| Unknown | 3 | 0.1 | 4 | 0.2 | 7 | 0.1 |
NOTE. Follow-up censored among 619 tamoxifen-assigned women at time of selective crossover to letrozole. Disease-free survival events that occurred after selective crossover were not included (n = 21 DFS events; n = 5 deaths; and n = 6 distant recurrences ignored relative to intention-to-treat analysis).
Abbreviations: NOS, not otherwise specified; NHL, non-Hodgkin's lymphoma.
*
Disease-free survival events.
†
Data requested but not received.